Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

131.85 -0.80 (-0.60%)
Streaming Delayed Price Updated: 1:21 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
2 Value Stocks I'm Buying Right Now
Via The Motley Fool
Topics Economy
Exposures Interest Rates
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
Via The Motley Fool
Topics Intellectual Property Retirement
Exposures Intellectual Property Pension
3 Relatively Safe Stocks to Buy Right Now
Via The Motley Fool
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Investors Are Flocking to These 3 Vanguard Sector ETFs. Should You Buy Them Too?
Via The Motley Fool
Topics ETFs Economy Government
Exposures Economy Political Tariff
Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Where Abbott Laboratories Stands With Analysts
Via Benzinga
Why Abbott Laboratories Stock Leaped by Almost 4% on Thursday
Via The Motley Fool
Which S&P500 stocks are moving on Thursday?
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session. 
Via Chartmill
What's going on in today's session: S&P500 movers
Stay informed about the performance of the S&P500 index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
From Rookie Mistakes To $10K/Year In Dividends – Military Veteran Who 'Made A Few Great Plays' Shares His 10 Biggest Bets
Via Benzinga
What Does the Market Think About Abbott Laboratories?
Via Benzinga
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income
Via The Motley Fool
No Quick Fix For This Market
Despite the pullback, we have found numerous opportunities which we discuss in this video using technical analysis. 
Via Talk Markets
Topics Stocks / Equities
What Does the Market Think About Abbott Laboratories?
Via Benzinga
Decoding Abbott Laboratories's Options Activity: What's the Big Picture?
Via Benzinga
Friday's session: top gainers and losers in the S&P500 index
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
These S&P500 stocks are gapping in today's session
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends. 
Via Chartmill
Q4 Earnings Roundup: CooperCompanies (NASDAQ:COO) And The Rest Of The Medical Devices & Supplies - Diversified Segment
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the medical devices & supplies - diversified stocks, including CooperCompanies (NASDAQ:COO) and its peers. 
Via StockStory
3 Reasons to Avoid ABT and 1 Stock to Buy Instead
Abbott Laboratories’s 16.6% return over the past six months has outpaced the S&P 500 by 12.8%, and its stock price has climbed to $136.50 per share. This run-up might have investors contemplating their... 
Via StockStory
Topics Stocks
Exposures US Equities
Recent Report Shows That Sen. Shelley M Capito Sold Up to $75K Worth of Comcast Stock
Via Benzinga
Florida Rep. Jared Moskowitz Sold Up to $15K Worth of West Pharmaceutical Servs Stock
Via Benzinga
2 Dependable Dividend Stocks That Can Pay You for Life
Via The Motley Fool
Indications Suggest ABBOTT LABORATORIES (NYSE:ABT) Could Be on the Verge of a Breakout.
Exploring ABBOTT LABORATORIES's Technical Signals and Breakout Potential: ABBOTT LABORATORIES is showing promising signs of setting up for a breakout. 
Via Chartmill
3 Reasons ABBV is Risky and 1 Stock to Buy Instead
AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six months. At the same time, the S&P 500 has returned 5.1%. 
Via StockStory
Topics Stocks
Exposures US Equities
Medical Devices & Supplies - Diversified Stocks Q4 Teardown: Stryker (NYSE:SYK) Vs The Rest
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at medical devices & supplies - diversified... 
Via StockStory
Q4 Earnings Roundup: Baxter (NYSE:BAX) And The Rest Of The Medical Devices & Supplies - Diversified Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q4,... 
Via StockStory
Biotech Stocks Stay Strong Through A Period Of Uncertainty In The Market
Many analysts are feeling better about the prospects for healthcare stocks in 2025. 
Via Talk Markets
Topics ETFs Stocks / Equities
Q4 Earnings Highs And Lows: Neogen (NASDAQ:NEOG) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQ:NEOG) and its peers. 
Via StockStory
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts highlighted long-term growth potential. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.